Abstract
Monoclonal antibody (mAb) against CD133 antigen is a stem marker of human tumor cells. Strain ICO-401 was prepared by cell fusion of murine myeloma NS-1 cells with splenocytes of BALB/ C mice, pre-immunized three times with an interval of two weeks with the cells of human melanoma mel IbrEE34RMCR. Merging was conducted with solution PEG/DMSO. Screening of mAb ICO-401 was performed on human melanoma cell lines from FSBI «N.N. Blokhin RCRC» collection which differ in the expression of CD133 antigen. Antigen expression was evaluated in immunofluorescence reaction by flow cytometer BD FACSCanto TM II. ICO-401 was compared with commercial mAb against CD133 antigen. The results indicated that both mAb recognize the same antigen, but bind to different epitops.
Highlights
Monoclonal antibody against CD133 antigen is a stem marker of human tumor cells
The results indicated that both Monoclonal antibody (mAb) recognize the same antigen, but bind to different epitops
Zhang S., Balch C., Chan M.W. et al Identification and characterization of ovarian cancer-initiating cells from primary human tumors // Cancer Res. – 2008. – 68. – P. 4311–20
Summary
Барышников МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ICO-401 ПРОТИВ АНТИГЕНА CD133 ФГБУ «РОНЦ им. Получены МКА против антигена CD133 – маркера стволовых опухолевых клеток человека. Штамм ICO401 получали путем слияния клеток мышиной миеломы NS-1 с клетками селезенки мышей линии BALB/C, предварительно трехкратно иммунизированных с интервалом в две недели клетками меланомы кожи человека линии mel IbrEE34RMCR. Для скрининга полученных МКА ICO-401 использовали клеточные линии меланомы человека из коллекции ФГБУ «РОНЦ им. Экспрессию антигена оценивали в РИФ на проточном цитофлуориметре BD FACSCantoTMII. МКА ICO-401 сравнивали с коммерческими МКА против антигена СD133, показано, что оба антитела распознают один и тот же антиген, но связываются с разными эпитопами. Ключевые слова: моноклональные антитела, CD133, стволовые опухолевые клетки, меланома кожи человека, проточная цитометрия.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
